Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
SIB 1757 is an antagonist of metabotropic glutamate receptor 5a (mGluR5a).1 It selectively inhibits glutamate-induced calcium release and quisqualate-induced phosphoinositol accumulation in fibroblasts expressing human mGluR5a (IC50s = 0.37 and 3.1 µM, respectively) over mGluR1b-expressing fibroblasts (IC50s = >100 µM for both). SIB 1757 is also selective for mGluR5a over mGluR2, mGluR3, mGluR4a, mGluR6, mGluR7b, mGluR8 (IC50s = >100 µM for all), as well as AMPA, kainate, and NMDA receptors (IC50s = >30 µM for all). It inhibits phosphoinositol accumulation induced by the group I mGluR agonist (S)-3,5-DHPG (Item No. 14411) in isolated neonatal rat hippocampus and striatum (IC50s = 5.2 and 10.1 µM, respectively). Intrathecal administration of SIB 1757 (0.01 µg/animal) increases the paw withdrawal threshold in a rat model of neuropathic pain induced by spinal nerve ligation.2
WARNING This product is not for human or veterinary use.
1. SIB-
2. Peripheral and spinal antihyperalgesic activity of SIB-